|
|||||
|
|
Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein |
|
| Authors: | Asisa Volz Alexandra Kupke Fei Song Sylvia Jany Robert Fux Hosam Shams-Eldin J?rg Schmidt Christin Becker Markus Eickmann Stephan Becker Gerd Sutter |
| Affiliation: | aGerman Center for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Munich, Germany;bGerman Center for Infection Research (DZIF), Institute of Virology, Philipps University Marburg, Marburg, Germany;cUniversity of Giessen Lung Center, Department of Internal Medicine II, Section of Infectious Diseases, Giessen, Germany |
| Abstract: | Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8+ T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine. |
| Keywords: | |